{
  "docId": "019de077-8566-7247-8a65-bb40d287c138",
  "docSlug": "3a5ef691e659aba2296672e3bbfa035c",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 36,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The table uses blue highlighting to emphasize the higher severity metrics in the EBO Ph 2 group.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/10",
  "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138",
  "deckJsonHref": "/decks/019de077-8566-7247-8a65-bb40d287c138.json",
  "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.23,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "ALIS= Amikacin liposome inhalation suspension; FC= Fibrocavitary; NB= Nodular brochiectatic",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ee91b7f-786e-42a2-b6f3-6b4f04b4ba97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.33,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "High rates of difficult-to-treat cavitary and fibrocavitary disease; Nearly a decade of disease duration; Significant population refractory or resistant to Arikayce / amikacin; High levels of multi-drug resistance; Microbial complexity and complex lung anatomy present challenges to successful bacterial eradication; Suggests that sputum culture conversion may not be appropriate secondary endpoint for oral therapies in TR-MAC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "399d8ada-7e28-47ce-8c1a-a443c523db9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.39,
        "y": 0.78
      },
      "kind": "source-note",
      "text": "* Caution should be exercised when comparing data across independent studies",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea7cd639-ed97-49cd-a0e7-997e768c6838",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.58,
        "x": 0.39,
        "y": 0.21
      },
      "kind": "table",
      "text": "Characteristic, EBO Ph 2 (n=80), CONVERT (n=336)*; Non-cavitary NB (%), 47.5%, 86.6%; Cavitary (C-NB and FC) (%), 52.5%, 13.4%; Disease duration (years), 9.3, 3.0-4.0; ALIS usage @ baseline, 18.8%, 0; Macrolide resistant @ baseline, 32.2%, 21.8%; Amikacin resistant @ baseline, 61.7%, 0",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc156a72-c851-4370-a6e7-cd2c495326a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.69,
        "x": 0.025,
        "y": 0.04
      },
      "kind": "title",
      "text": "EBO-301 Enrolled a Severely Refractory Population",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb65c8b0-10dd-4b22-9183-30a75116423e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "97a1ede8-85ba-45c5-94c2-981cd0dfd720",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document presents clinical trial results and other traction metrics for AN2 Therapeutics' pipeline candidates.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}